High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma

Tumor-associated macrophages in diffuse large B-cell lymphoma

“…Whereas Nam et al 8 reported similar findings, as mentioned above, and the study by Cai et al 15 also showed that CD68 is a marker of poor outcome in CHOP-treated DLBCL patients, the studies by Hasselblom et al, 16 Meyer et al 17 and Coutinho et al 18 did not reveal significant associations between CD68 protein expression and survival. Furthermore, Wada et al 19 and Marchesi et al 20 reported that an M2 macrophage phenotype, as defined by double staining for CD68 and CD163, is associated with adverse outcome in R-CHOP-treated patients, whereas an M1 phenotype is not. How can these discrepancies be explained?…”

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes

“…Recent studies demonstrated the important function of TAMs in the progression of cancers 15, 16, 17, 30. Hans et al.…”

“…It is demonstrated that macrophages possess anti‐tumor or tumor‐promotion effects, depending on their acquired immune‐phenotype (M1 or M2) which express different levels of chemokines, cytokines. TAMs (M2 phenotype) predict poor outcome in DBLCL patients‐treated with chemotherapy 15, 16, 17. Polymorphisms of host cytokines and immunity‐related genes were reported to play very important roles in predicting survival of DLBCL patients 7.…”

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

“…37 Lymphoma lesions are infiltrated with CD163+ M2 macrophages and their presence is associated with worse prognosis. 38,39 The presence of MDSCs is correlated to a poor overall survival. 40 However, the role of Tregs in Bcell malignancy is contradictive and has even been associated to a better prognosis.…”